Big tech says AI can find a cure for cancer. So where is it?

Big tech companies have made grand claims about AI's potential to find a cure for cancer. The question is, where is it? The evidence for these claims is emerging in the form of validation studies, such as the recent Mayo Clinic study that detected pancreatic cancer up to 3 years before diagnosis. This study is a landmark validation of AI's ability to identify cancer early, but it is just one piece of the puzzle.

The development of AI-driven cancer treatments is a complex process that involves multiple stakeholders, including researchers, clinicians, and regulatory bodies. The Mayo Clinic study is a significant step forward in the use of AI in cancer research and care delivery. The study's findings have been reported by The Guardian, and are a testament to the potential of AI to transform cancer treatment. However, the development of AI-driven cancer treatments is a long-term process that requires significant investment and collaboration.

The caveat is that the development of AI-driven cancer treatments is a complex process that involves multiple stakeholders and regulatory hurdles. While AI has shown promise in identifying cancer early, the development of AI-driven cancer treatments requires significant investment and collaboration between researchers, clinicians, and regulatory bodies. The pharmaceutical industry stands to gain from the development of AI-driven cancer treatments, but the process is far from straightforward.